Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alaunos Therapeutics (TCRT) Other Operating Expenses (2021 - 2023)

Alaunos Therapeutics (TCRT) has disclosed Other Operating Expenses for 12 consecutive years, with -$2000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Operating Expenses changed N/A year-over-year to -$2000.0, compared with a TTM value of -$3000.0 through Sep 2025, down 100.08%, and an annual FY2023 reading of $4.5 million, up 3487.22% over the prior year.
  • Other Operating Expenses was -$2000.0 for Q3 2025 at Alaunos Therapeutics, down from -$1000.0 in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $3.7 million in Q4 2023 and bottomed at -$244000.0 in Q2 2023.
  • Average Other Operating Expenses over 5 years is $789714.3, with a median of -$1000.0 recorded in 2024.
  • The sharpest move saw Other Operating Expenses plummeted 83.46% in 2023, then tumbled 100.03% in 2024.
  • Year by year, Other Operating Expenses stood at $740000.0 in 2021, then tumbled by 117.97% to -$133000.0 in 2022, then surged by 2911.28% to $3.7 million in 2023, then crashed by 100.03% to -$1000.0 in 2024, then plummeted by 100.0% to -$2000.0 in 2025.
  • Business Quant data shows Other Operating Expenses for TCRT at -$2000.0 in Q3 2025, -$1000.0 in Q4 2024, and $3.7 million in Q4 2023.